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RELIABILITY OF ANIMAL MODELS IN CAPSID TESTING
The reliability of the available animal models for comparison of transduction of the liver by different AAV serotypes has been questioned. 7 In the AIP trial, 4 the high-dose group received 1.8 × 10
13 vg kg − 1 , which is equivalent to the therapeutic threshold needed to achieve a correction of the murine phenotype (1.25 × 10 13 vg kg − 1 ), 8 but lower than that required for supraphysiological enzymatic activity in Rhesus macaques (5 × 10 13 vg kg − 1 ). 5 AAV5 is currently used in a clinical trial for haemophilia B with the same transgene cassette used by Nathwani et al. (http://www.uniqure.com/news/320/182/uniQurePresents-Updated-Clinical-Data-in-Patients-with-Severe-Hemophi lia-B-Demonstrating-up-to-9-Months-of-Sustained-Levels-of-Fac tor-IX-Activity-and-Therapeutic-Effect.html. In.). Nine months post infusion, the low-dose group, who received 5 × 10 12 vg kg − 1 , showed a plasma FIX of 5.4% (range 3.1-6.7%; n = 5) (http://www. uniqure.com/news/320/182/uniQure-Presents-Updated-ClinicalData-in-Patients-with-Severe-Hemophilia-B-Demonstrating-upto-9-Months-of-Sustained-Levels-of-Factor-IX-Activity-and-Ther apeutic-Effect.html. In.), which is similar to the level observed in the high-dose group of the AAV8 trial receiving 2 × 10 12 vg kg − 1 (plasma FIX of 5.1%, range 2.9-7.1%; n = 6) 4 months post infusion. 3 These results suggest that, to obtain similar plasma FIX levels to those achieved in AAV8 trial, administration of 2.5-fold more AAV5 vector is necessary.
Although this assumption is made on the basis of a small number of treated subjects, and confounded by different methods of production, titration and purification, it supports data obtained after intravenous injection in different animal models:
i In murine models of AIP, AAV5 resulted in 10-fold less liver transduction compared with AAV8. 8 ii In Gunn rats, AAV5 vector was inefficient at restoring metabolic activity and achieved three times lower copy number compared with AAV8. 6 iii In Rhesus macaques, AAV5 vector produced slightly lower plasma FIX in adult animals with slower kinetics compared with AAV8, 9 lower hepatocyte transduction after fetal intrahepatic venous injection and lower plasma FIX 2 months post injection ( o1 μg ml
achieved transduction of 10-fold fewer of human hepatocytes than AAV8 (0.1 versus 1.1%, respectively).
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Further results from larger human trials will provide further information on the reliability of animal data, which will accelerate the development of liver-directed gene therapy.
EPISOMAL VERSUS ENDOGENOUS GENE EXPRESSION
D'Avola et al. 4 are the first to report data from human liver biopsies after AAV treatment. Interestingly, the liver vector copy number 1 year post injection did not correlate with the escalating doses of vector received. This finding is in contrast with the studied tissues from animal models 5, 8 or plasma FIX levels in haemophilia B trial. 3 In liver biopsies with high vector copy number of the transgene codon-optimised PBG deaminase (coPBGD) (patients 2, 5 and 7), coPBGD mRNA expression compared with endogenous PBGD (normalised by DNA copy number) was lower by 45%, 76% and 36%, respectively. 4 In AAVmediated gene therapy, most of the transgene DNA copies persist as non-integrated episomes. Different episomal expression compared with the endogenous gene of interest underpins results observed in an ornithine transcarbamylase 12 -deficient Spf ash mouse model. Untreated Spf ash mice with a 5-7% wild-type residual ornithine transcarbamylase activity become hyperammonaemic after a short hairpin RNA (shRNA)-mediated knockdown of the endogenous ornithine transcarbamylase activity to 0-2.5%. In shRNA-injected Spf ash mice, the level of AAV-encoded ornithine transcarbamylase activity required to normalise ammonaemia was threefold higher than the residual ornithine transcarbamylase activity in untreated Spf ash mice. 13 An AAV pattern of transduction not reproducing the physiological metabolic zonation of the liver might have had an additional role. Although these findings rely on a small cohort and require caution in interpretation, various explanations might account for a different episomal expression such as inadequate chromatinisation, incomplete circularisation of the AAV genome altering the constitution of the open reading frame for transgene expression or inverted terminal repeats recombination. The exact mechanism for this phenomenon is yet to be identified.
FUNCTIONAL METABOLIC ASSAYS AS EFFICACY END POINTS IN CLINICAL TRIALS
Finally, the use of metabolite levels as primary end point for trials in metabolic diseases can be questioned. These surrogate markers often reflect a static picture, and remain indirect assessments of the metabolic flux and its environmental or epigenetic regulation. Indeed, haem biosynthesis is mainly regulated by haem-mediated inhibitory feedback of the transcription of ALA-synthetase, but other parameters can exert an influence such as glucose intake, stress, drugs, circadian rhythm, 14 and may potentially affect ALA and PBG results. Thus, whenever feasible, stable isotope studies would be better indicators of the in vivo dynamics of the pathway. For example, oral administration of N 15 -labelled glycine can monitor the biosynthesis of haem and its intermediate compounds in physiology and patients with inherited porphyrias. 15 This approach has been successfully used in other metabolic pathways like the urea cycle to assess ureagenesis utilising either N 15 -labelled urea in animal models after AAV-mediated gene therapy 16, 17 or C 13 -labelled acetate in humans for accurately stratifying the disease severity in ornithine transcarbamylase deficiency. 18 Furthermore, the use of clinically relevant end points would not only provide better assessment of the effect of therapy, but may be viewed more favourably by regulatory bodies.
